Scholarlink

Background <p>Prostate-specific membrane antigen (PSMA) PET/CT has transformed prostate cancer (PCa) management by improving lesion detection and guiding treatment decisions across disease stages. Following the first paper of the Italian PSMA Survey focused on technical aspects and primary staging, this second analysis explores its clinical use in PSA persistence after radical prostatectomy, biochemical recurrence (BCR), hormone-sensitive metastatic (mHSPC), and castration-resistant metastatic (mCRPC) settings.</p> Methods <p>A national cross-sectional survey was conducted jointly by five Italian scientific societies involving nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists (AIMN, AIOM, AIRO, SIU, SIUrO) and the Meet-URO cooperative group. Dedicated sections addressed the adoption, timing, and perceived clinical impact of PSMA PET/CT in PSA persistence after radical prostatectomy, BCR, mHSPC, and mCRPC. Responses were analysed descriptively and stratified by medical competences (clinicians versus nuclear medicine physicians).</p> Results <p>PSMA PET/CT emerged as the preferred imaging modality in all clinical scenarios. In PSA persistence and BCR, 87–95% of respondents selected PSMA PET as first-line imaging, most often performed at PSA levels of 0.2–0.5 ng/mL. When negative, more than two-thirds recommended repeating PSMA PET/CT after PSA further rise. In mHSPC, over 80% of clinicians applied the CHAARTED criteria directly to PSMA PET findings, while PSMA PET/CT was also widely used for restaging and therapy monitoring. In mCRPC, PSMA PET/CT was routinely used for baseline and follow-up imaging. Most clinicians considered the low-dose CT component sufficient for radioligand therapy (RLT) eligibility, while [<sup>18</sup>F]Fluorodeoxyglucose (FDG) PET was reserved for selected high-risk or discordant cases.</p> Conclusion <p>PSMA PET/CT has become the central imaging modality in the management of advanced PCa in Italy. Its adoption has progressed faster than supporting evidence, underscoring the need for prospective validation, implementation of harmonised interpretation criteria, and unified national recommendations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月14日

查看全文
  • Matteo Bauckneht,
  • Laura Evangelista,
  • Luca Sofia,
  • Marco Maccauro,
  • Angelina Filice,
  • Maria Luisa De Rimini,
  • Orazio Caffo,
  • Carlo Messina,
  • Marco Maruzzo,
  • Giada Pinterpe,
  • Marco Krengli,
  • Andrea Mari,
  • Riccardo Schiavina,
  • Sergio Bracarda,
  • Rolando Maria D’Angelillo,
  • Alberto Lapini,
  • Paolo Andrea Zucali,
  • Giuseppe Fornarini,
  • Raffaela Abate,
  • Domenico Albano,
  • Andrea Alberti,
  • Simona Allis,
  • Filippo Alongi,
  • Pierpaolo Alongi,
  • Francesca Ambrosini,
  • Luca Antonelli,
  • Filippo Antonica,
  • Gabriella Arena,
  • Demetrio Aricò,
  • Francesco Atzori,
  • Marco Badalamenti,
  • Cinzia Baiocco,
  • Valentina Baldazzi,
  • Alfonso Baldoncini,
  • Michelangelo Bambaci,
  • Gian Franco Bardino,
  • Lilia Bardoscia,
  • Lucia Barsacchi,
  • Domenico Barzaghi,
  • Umberto Basso,
  • Antonino Battaglia,
  • Glauco Bertello,
  • Andrea Bianchi,
  • Gabriele Bignante,
  • Michele Boero,
  • Monica Boitano,
  • Amedeo Bonfiglio,
  • Simona Borghesi,
  • Paolo Borghetti,
  • Eugenio Borsatti,
  • Nicolò Borsellino,
  • Roberto Bortolus,
  • Valentina Borzillo,
  • Isa Bossi Zanetti,
  • Annalisa Bramati,
  • Tommaso Brancato,
  • Alessio Bruni,
  • Michele Bruno,
  • Giovanni Brusasco,
  • Lorenza Bruschieri,
  • Alberto Buffoli,
  • Luca Burroni,
  • Giovanni Busacca,
  • Sebastiano Buti,
  • Emanuela Cagna,
  • Fabio Calabrò,
  • Natale Daniele Calandruccio,
  • Carmelo Caldarella,
  • Oriana Calisto,
  • Davide Campobasso,
  • Giuseppe Candita,
  • Domenico Cante,
  • Tommaso Carfagno,
  • Paolo Carlini,
  • Paola Caroli,
  • Lucio Carozzi,
  • Giuseppe Carrieri,
  • Salvatore Carrozza,
  • Michele Caruso,
  • Emanuele Casciani,
  • Claudia Caserta,
  • Angelo Castello,
  • Alessandra Castelluccia,
  • Calogero Casà,
  • Simona Cauda,
  • Alessia Cavo,
  • Francesco Ceci,
  • Greta Celesti,
  • Rita Cengarle,
  • Linda Cerbone,
  • Valentina Ceriani,
  • Giuseppe Chiacchio,
  • Francesco Chierigo,
  • Angelo Andrea Chirillo,
  • Stefano Ciccarelli,
  • Cosimo Ciotta,
  • Edoardo Cisero,
  • Angelina Cistaro,
  • Alessandra Cocchi,
  • Giorgia Cocco,
  • Sarah Colangione,
  • Federico Colombo,
  • Vincenza Conteduca,
  • Andrea Conti,
  • Nadia Cordua,
  • Alessandro Crestani,
  • Cristiano Vincenzo Emilio Cristini,
  • Francesco Cuccia,
  • Andrea D’Arienzo,
  • Alberto Dalla Volta,
  • Francesca De Felice,
  • Alberto De Gobbi,
  • Diego De Palma,
  • Nicola De Rosa,
  • Giuseppe De Vincentis,
  • Rocco De Vivo,
  • Silvia Angela Debonis,
  • Teresa Del Giudice,
  • Nerina Denaro,
  • Beatrice Detti,
  • Francesco Di Clemente,
  • Luciana Di Cristina,
  • Rossella Di Franco,
  • Luca Di Gianfrancesco,
  • Andrea Di Giorgio,
  • Eugenio Di Giorgio,
  • Stefania Di Girolamo,
  • Fernando Di Gregorio,
  • Giuseppe Di Lorenzo,
  • Giuseppe Di Lucca,
  • Marilena Di Napoli,
  • Tania Di Raimondo,
  • Roberta Di Rocco,
  • Ettore Di Trapani,
  • Giuseppe Dinoi,
  • Michele Dionese,
  • Maria Isabella Donegani,
  • Paola Ermacora,
  • Miguel Espindola,
  • Gaetano Facchini,
  • Martina Fanelli,
  • Patrizia Farina,
  • Fabio Ferrarese,
  • Milena Ferro,
  • Pier Francesco Ferrucci,
  • Rossella Filice,
  • Antonella Fontana,
  • Lucia Fraino,
  • Giulio Francolini,
  • Viviana Frantellizzi,
  • Ciro Franzese,
  • Dario Franzese,
  • Nicola Frega,
  • Gianluca Frusciante,
  • Daniele Galanti,
  • Letizia Galeasso,
  • Antonio Galfano,
  • Rosj Gallicchio,
  • Michele Ganovelli,
  • Ludovico Maria Garau,
  • Elisabetta Garibaldi,
  • Pietro Garlatti,
  • Federico Garrou,
  • Donatello Gasparro,
  • Sabrina Genovese,
  • Domenico Germano,
  • Antonio Ghidini,
  • Giulia Giacoppo,
  • Gianluca Giannarini,
  • Giuseppe Giovinazzo,
  • Emilio Francesco Giunta,
  • Giorgia Maria Granese,
  • Francesco Grillone,
  • Liliana Guadagni,
  • Luca Guerra,
  • Priscilla Guglielmo,
  • Cesare Guida,
  • Andrea Guttilla,
  • Francesco Guzzi,
  • Vincenzo Iorio,
  • Cinzia Iotti,
  • Margarita Kirienko,
  • Salvatore La Mattina,
  • Anna La Salvia,
  • Valeria Lami,
  • Andrea Lancia,
  • Francesco Lanfranchi,
  • Tiziana Lanzolla,
  • Riccardo Laudicella,
  • Mariadea Lavalle,
  • Grazia Lazzari,
  • Lucia Leccisotti,
  • Edoardo Lenci,
  • Virginia Liberini,
  • Giovanni Longo,
  • Chiara Lorubbio,
  • Daria Maccora,
  • Michele Maffezzoli,
  • Francesca Maggio,
  • Gaia Mango,
  • Piero Mannone,
  • Cristina Mantarro,
  • Guglielmo Mantica,
  • Andrea Marchetti,
  • Lorenza Marino,
  • Francesco Marletta,
  • Anna Rita Marsella,
  • Fabio Matrone,
  • Federica Matteucci,
  • Rocco Mazza,
  • Alberto Miceli,
  • Chiara Miceli,
  • Eugenio Miglioranza,
  • Francesca Migliozzi,
  • Elisa Milan,
  • Veronica Mollica,
  • Francesco Montagnani,
  • Gabriele Montefusco,
  • Marianna Montesano,
  • Franco Morelli,
  • Stefano Moroso,
  • Rocco Morra,
  • Claudia Mosillo,
  • Micaela Motta,
  • Claudia Mucciarini,
  • Fernando Munoz,
  • Daniela Musio,
  • Salvatore Mussari,
  • Anna Giulia Nappi,
  • Angelo Naselli,
  • Antonio Nicocia,
  • Deborah Olivieri,
  • Luca Orecchia,
  • Mattia Falchetto Osti,
  • Sara Pacella,
  • Roberto Pacelli,
  • Stefano Panareo,
  • Federico Paolieri,
  • Rosario Paratore,
  • Vincenzo Parisella,
  • Martina Parisi,
  • Nadia Pasinetti,
  • Elisa Peci,
  • Michele Pennisi,
  • Giovanna Pepe,
  • Pietro Pepe,
  • Massimo Perachino,
  • Annarita Perillo,
  • Elisabetta Perrone,
  • Dario Placido Pesce,
  • Arnoldo Piccardo,
  • Lorena Picori,
  • Francesco Pierantoni,
  • Claudia Piombino,
  • Teresa Pironti,
  • Mario Pirozzi,
  • Valeria Pirro,
  • Marco Pisino,
  • Daniele Antonio Pizzuto,
  • Angelo Platania,
  • Camillo Porta,
  • Carlo Poti,
  • Francesco Prata,
  • Fabrizio Presicce,
  • Giuseppe Procopio,
  • Giulia Puccini,
  • Andrea Maria Onofrio Quattrocchi,
  • Marco Raddi,
  • Stefano Raffa,
  • Andrea Rappazzo,
  • Francesca Rastelli,
  • Alessia Reali,
  • Sara Elena Rebuzzi,
  • Konudula Sreenivasa Reddy,
  • Davide Renna,
  • Isabella Ricci,
  • Giulia Rinaldi,
  • Alessio Rizzo,
  • Marcello Rodari,
  • Giovambattista Roda’,
  • Daniele Romagnoli,
  • Pasquale Romano,
  • Andrea Romei,
  • Marco Roscigno,
  • Rosalba Rossello,
  • Claudio Rossetti,
  • Sabrina Rossetti,
  • Guido Rovera,
  • Giandomenico Roviello,
  • Giuseppe Rubini,
  • Livia Ruffini,
  • Lorenzo Ruggera,
  • Alessia Ruggiero,
  • Giorgio Ivan Russo,
  • Roberto Sabatina,
  • Nello Salesi,
  • Alessia Salfi,
  • Enrico Sammarco,
  • Alessandro Samuelly,
  • Daniela Sanna,
  • Daniele Santini,
  • Donata Sartori,
  • Teodoro Sava,
  • Mario Savino,
  • Andrea Sbrana,
  • Sarah Scagliarini,
  • Antonio Francesco Scarale,
  • Maurizio Schifilliti,
  • Rosa Sciuto,
  • Barbara Scola,
  • Matteo Sepulcri,
  • Flavia Serafini,
  • Marco Andrea Signor,
  • Alberto Signore,
  • Giustino Silvestro,
  • Mariella Sorarù,
  • Corrado Spatola,
  • Gian Paolo Spinelli,
  • Antonio Spinoso,
  • Marco Stellato,
  • Redona Tafili,
  • Giorgia Timon,
  • Giuseppe Tirino,
  • Alessandra Tognoni,
  • Liboria Maria Grazia Travagliato,
  • Emanuela Trenti,
  • Giuseppe Trifiro’,
  • Barbara Turi,
  • Luca Urso,
  • Luca Vaggelli,
  • Antonio Vavallo,
  • Antonio Vento,
  • Elena Verzoni,
  • Giovanni Vicario,
  • Claudio Vitale,
  • Flaminia Vocaturo,
  • Suela Vukcaj,
  • Francesca Zacchi,
  • Ilaria Zampiva,
  • Elisa Zanardi,
  • Diego Zara,
  • Andrea Zivi

摘要

Background

Prostate-specific membrane antigen (PSMA) PET/CT has transformed prostate cancer (PCa) management by improving lesion detection and guiding treatment decisions across disease stages. Following the first paper of the Italian PSMA Survey focused on technical aspects and primary staging, this second analysis explores its clinical use in PSA persistence after radical prostatectomy, biochemical recurrence (BCR), hormone-sensitive metastatic (mHSPC), and castration-resistant metastatic (mCRPC) settings.

Methods

A national cross-sectional survey was conducted jointly by five Italian scientific societies involving nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists (AIMN, AIOM, AIRO, SIU, SIUrO) and the Meet-URO cooperative group. Dedicated sections addressed the adoption, timing, and perceived clinical impact of PSMA PET/CT in PSA persistence after radical prostatectomy, BCR, mHSPC, and mCRPC. Responses were analysed descriptively and stratified by medical competences (clinicians versus nuclear medicine physicians).

Results

PSMA PET/CT emerged as the preferred imaging modality in all clinical scenarios. In PSA persistence and BCR, 87–95% of respondents selected PSMA PET as first-line imaging, most often performed at PSA levels of 0.2–0.5 ng/mL. When negative, more than two-thirds recommended repeating PSMA PET/CT after PSA further rise. In mHSPC, over 80% of clinicians applied the CHAARTED criteria directly to PSMA PET findings, while PSMA PET/CT was also widely used for restaging and therapy monitoring. In mCRPC, PSMA PET/CT was routinely used for baseline and follow-up imaging. Most clinicians considered the low-dose CT component sufficient for radioligand therapy (RLT) eligibility, while [18F]Fluorodeoxyglucose (FDG) PET was reserved for selected high-risk or discordant cases.

Conclusion

PSMA PET/CT has become the central imaging modality in the management of advanced PCa in Italy. Its adoption has progressed faster than supporting evidence, underscoring the need for prospective validation, implementation of harmonised interpretation criteria, and unified national recommendations.